Ernst Carrie L, Goldberg Joseph F
Department of Psychiatry, Cambridge Hospital, Cambridge, Massachusetts, USA.
J Clin Psychopharmacol. 2003 Apr;23(2):182-92. doi: 10.1097/00004714-200304000-00011.
A growing number of anticonvulsant drugs are receiving attention as possible mood stabilizers. This attention is based mainly on the assumption that the antimanic efficacy of anticonvulsants makes them suitable as mood stabilizers. However, their antidepressant properties have received less scrutiny. In this review, current evidence concerning the acute and prophylactic efficacy of divalproex, carbamazepine, gabapentin, lamotrigine, and topiramate in bipolar depression is evaluated. Clinical outcome data are considered, together with limitations of existing studies and the concept of unmet clinical needs. Findings in placebo-controlled trials suggest an acute and prophylactic antidepressant effect with lamotrigine monotherapy and more modest antidepressant benefits with other agents administered as monotherapies. Results of published studies are considered with respect to the conceptualization of mood stabilization as arising from antimanic and antidepressant efficacy in bipolar disorder.
越来越多的抗惊厥药物作为潜在的心境稳定剂受到关注。这种关注主要基于这样一种假设,即抗惊厥药物的抗躁狂疗效使其适合作为心境稳定剂。然而,它们的抗抑郁特性受到的审视较少。在本综述中,评估了丙戊酸、卡马西平、加巴喷丁、拉莫三嗪和托吡酯治疗双相抑郁的急性和预防性疗效的现有证据。考虑了临床结局数据,以及现有研究的局限性和未满足的临床需求的概念。安慰剂对照试验的结果表明,拉莫三嗪单药治疗有急性和预防性抗抑郁作用,而其他药物单药治疗的抗抑郁益处较小。已发表研究的结果是从双相情感障碍中抗躁狂和抗抑郁疗效产生心境稳定的概念角度来考虑的。